Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats.

This study adds to the growing body of evidence supporting the development of a potent 5-HT1A receptor agonist for treatment of peak-dose dyskinesia. PMID: 29572645 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29572645?dopt=Abstract

Source: Neurochemical Research - March 23, 2018 Category: Neuroscience Authors: Newman-Tancredi A, Varney MA, McCreary AC Tags: Neurochem Res Source Type: research

More News: Brain | Dyskinesia | Neurology | Neuroscience | Study